Leaflet: Information for the user
Bupivacaine Aurovitas 2.5 mg/ml solution for injection EFG
bupivacaine hydrochloride
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Bupivacaine Aurovitas contains the active substance bupivacaine hydrochloride, which belongs to a group of medicines called local anesthetics of the amide type. It produces a loss of sensation that is limited to a part of the body.
Bupivacaine is used to numb (anesthetize) parts of the body. It is used to prevent pain or to relieve it. It can be used for:
Do not useBupivacaineAurovitas
If any of the above applies to you, you should not be given bupivacaine. If in doubt, consult your doctor before you are given the bupivacaine injection solution.
Warnings and precautions
Consult your doctor before you start using Bupivacaine Aurovitas.
Children
In children under 12 years of age, since the use of some doses of bupivacaine for numbing parts of the body during surgical procedures has not been established in younger children. The use of bupivacaine in children under 1 year of age has not been established.
If you are not sure if any of the above applies to you, consult your doctor before you are given bupivacaine.
UsingBupivacaineAurovitas with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Taking some medicines together can be harmful. Remember that the hospital doctor may not be aware that you have recently started treatment for another illness. In particular, tell your doctor if you are taking:
The doctor should be informed of these medicines to be able to calculate the correct dose of bupivacaine for you.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Bupivacaine may pass into breast milk. If you are breastfeeding, you should consult your doctor about the options.
Driving and using machines
Bupivacaine may make you feel drowsy and affect your reaction speed. After receiving bupivacaine, you should not drive or use tools or machines until the next day.
BupivacaineAurovitas contains sodium
Patients on low-sodium diets should note that this medicine contains approximately 3.38 mg (or 0.15 mmol) of sodium per ml.
Bupivacaine will be given to you by a doctor with the necessary knowledge and experience in epidural anesthesia techniques.
The recommended dose that your doctor will give you will depend on the type of pain relief you need and where in the body the injection will be given. It will also depend on your body size, age, and physical condition. Usually, a single dose of sufficient duration can be given, but additional doses may be given if the surgical procedure is prolonged.
Bupivacaine will be given to you as an injection. The part of the body where the injection will be given will depend on the reason why you are being given bupivacaine. The doctor will give you bupivacaine in one of the following places:
When bupivacaine is injected into the body in one of these places, it prevents nerves from sending pain messages to the brain. The effect will wear off gradually once the medical procedure is finished.
Method of administration
The medicine is exclusively for percutaneous infiltration, peripheral nerve block(s), and central nervous block (caudal or epidural).
If you use more Bupivacaine Aurovitas than you should
It is unlikely that serious side effects will occur from using too much bupivacaine. They require special treatment and the doctor treating you has experience in dealing with these situations. The first signs that you are using too much bupivacaine are usually:
To reduce the risk of serious side effects, the doctor will stop giving you bupivacaine as soon as these signs appear. This means that if you experience any of these signs or if you think you have received more bupivacaine than you should, tell your doctor immediately.
The most serious side effects due to excessive administration of bupivacaine include muscle spasms, convulsions, and loss of consciousness.
If you forget to useBupivacaineAurovitas
If you think you have missed a dose, tell your doctor or nurse.
Do not use a double dose to make up for forgotten doses.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Severe allergic reactions (rare, may affect up to 1 in 1,000 people):
Tell your doctor immediately if you have a severe allergic reaction. The signs may include:
Other possible side effects:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Other possible side effects observed with other local anesthetics that may also be caused by bupivacaine include:
Other side effects in children and adolescents
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Medicines Agency (AEMPS) at www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the ampoule and carton after EXP. The expiry date is the last day of the month stated.
Do not use this medicine if you notice that the contents have changed color or if there are particles.
Bupivacaine Aurovitas is for single use. Discard the unused solution.
No special storage conditions are required.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition ofBupivacaineAurovitas
Each ml contains 2.5 mg of bupivacaine hydrochloride.
Each ampoule with 10 ml of solution contains 25 mg of bupivacaine hydrochloride.
Appearance of the product and pack contents
Injection solution.
Clear and colorless aqueous solution.
10 ml glass ampoules type I.
Each carton contains 1, 5, 10, 20, and 100 ampoules.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Eugia Pharma (Malta) Limited
Vault 14, Level 2, Valletta Waterfront
Floriana, FRN 1914
Malta
Manufacturer:
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000
Malta
You can request more information about this medicine from the local representative of the marketing authorization holder:
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Spain: | Bupivacaine Aurovitas 2.5 mg/ml solution for injection EFG |
Italy: | Bupivacaine Aurobindo |
Portugal: | Bupivacaine Aurovitas |
Date of last revision of this leaflet: November 2016
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
This information is intended only for healthcare professionals:
The disposal of unused medicine and all materials that have come into contact with it will be carried out in accordance with local regulations.
Injection solution.
The medicine is exclusively for percutaneous infiltration, peripheral nerve block(s), and central nervous block (caudal or epidural).
The doctor's experience and knowledge of the patient's physical condition are important for calculating the necessary dose. The minimum dose necessary for adequate anesthesia should be used. The dose limit should not be exceeded. A dose of 400 mg administered in 24 hours is well tolerated by the average adult. In pediatric patients, the minimum dose necessary for adequate anesthesia should be used.
For single use.
Only clear solutions that are practically free of particles should be used. The unused solution should be discarded.
Do not use this medicine after the expiry date which is stated on the ampoule and carton after EXP. The expiry date is the last day of the month stated.
Information on storage
No special storage conditions are required.